ReviewJournal of endocrinological investigation2023
Dysthyroid optic neuropathy: emerging treatment strategies.
Review in Journal of endocrinological investigation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Efficacy and safety of Tocilizumab for thyroid eye disease: a systemic review and Meta-analysis.Journal of endocrinological investigation · 2025Pooled it
- Post Hoc MRI Analysis of Orbital Soft Tissue Volumes Pre- and Post-Teprotumumab in Patients with Chronic, Low-Activity Thyroid Eye Disease.Ophthalmology and therapy · 2026Article
- Finite Element Analysis of Extraocular Muscle and Adipose-Dominant Pathogenesis in Thyroid Eye Disease With Clinical Implications.Translational vision science & technology · 2026Article
- Association Between Peripheral IL-2Journal of clinical medicine · 2026Article
- The Visual Function of Emergent Transnasal Endoscopic Orbital Decompression Surgery for Patients With Steroid-Resistant Dysthyroid Optic Neuropathy.The Journal of craniofacial surgery · 2026Article
- Reliability of extraocular muscle biomechanics in the evaluation of disease activity in thyroid eye disease.Journal of endocrinological investigation · 2026Article
- Relationship between serologically abnormal lipid metabolism and dysthyroid optic neuropathy in patients with thyroid-associated ophthalmopathy.Journal of endocrinological investigation · 2026Article
- The Diagnostic Value of Mean Apparent Propagator-MRI in Dysthyroid Optic Neuropathy: A Quantitative Analysis of the Entire Visual Pathway.CNS neuroscience & therapeutics · 2026Article
- [The use of tocilizumab in severe glucocorticoid-resistant endocrine ophthalmopathy with optic neuropathy in clinical practice].Problemy endokrinologii · 2026Article
- A combined model of BCVA, TRAb, and NLR predicts response to intravenous methylprednisolone in dysthyroid optic neuropathy.Frontiers in medicine · 2026Article
- Medium-dose intravenous methylprednisolone pulse therapy for thyroid-associated orbitopathy.International journal of ophthalmology · 2026Article
- Quantitative analysis of orbital soft tissue for the detection of dysthyroid optic neuropathy in patients with thyroid-associated ophthalmopathy, based on three-dimensional cube fast spin-echo Flex.Quantitative imaging in medicine and surgery · 2025Article
- A Nationwide Survey by the Korean Society of Ophthalmic Plastic and Reconstructive Surgery (KSOPRS) on the Management of Thyroid Eye Disease in South Korea.Korean journal of ophthalmology : KJO · 2025Article
- Predicting dysthyroid optic neuropathy in moderate-to-severe thyroid eye disease: a clinically applicable nomogram.European thyroid journal · 2025Article
- Multiparametric MRI for Diagnosing Dysthyroid Optic Neuropathy: Added Value of Magnetization Transfer Imaging.Korean journal of radiology · 2025Article
- No retinopathy after orbital irradiation in patients with thyroid eye disease - a follow up study.Frontiers in endocrinology · 2025Article
- The burden of illness in thyroid eye disease: current state of the evidence.Frontiers in ophthalmology · 2025Review
- Optic nerve compression associated with visual cortex functional alteration in dysthyroid optic neuropathy: A combined orbital and brain imaging study.CNS neuroscience & therapeutics · 2024Article
- Article
- Tocilizumab use for optic nerve compression in thyroid eye disease: a prospective longitudinal cohort.International ophthalmology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDysthyroid optic neuropathy (DON) is a rare sight-threatening complication of Graves' disease. First-line treatment for DON consists of high-dose intravenous methylprednisolone (ivMP), followed by immediate orbital decompression (OD) if the response is poor or absent as recommended by the 2021 European Group on Graves' orbitopathy guidelines. The safety and efficacy of the proposed therapy have been proven. However, consensus regarding possible therapeutic options for patients with contraindications to ivMP/OD or resistant form of disease is missing. This paper aims to provide and summarize all available data regarding possible alternative treatment strategies for DON.
methodsA comprehensive literature search within an electronic database was performed including data published until December 2022.
resultsOverall, 52 articles describing use of emerging therapeutic strategies for DON were identified. Collected evidence indicates that biologics, including teprotumumab and tocilizumab, may be considered as an important possible treatment option for DON patients. Rituximab should be avoided in DON due to conflicting data and risk of adverse events. Orbital radiotherapy could be beneficial for patients with restricted ocular motility classified as poor surgical candidates.
conclusionOnly a limited number of studies have been dedicated to the therapy of DON, mostly retrospective with a small sample size. Clear criteria regarding diagnosis and resolution of DON do not exist, which restricts comparison of therapeutic outcomes. Randomized clinical trials and comparison studies with long-term follow-ups are necessary to verify the safety and efficacy of each therapeutic option for DON.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.